These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26720709)

  • 1. Novel Zn2+ Modulated GPR39 Receptor Agonists Do Not Drive Acute Insulin Secretion in Rodents.
    Fjellström O; Larsson N; Yasuda S; Tsuchida T; Oguma T; Marley A; Wennberg-Huldt C; Hovdal D; Fukuda H; Yoneyama Y; Sasaki K; Johansson A; Lundqvist S; Brengdahl J; Isaacs RJ; Brown D; Geschwindner S; Benthem L; Priest C; Turnbull A
    PLoS One; 2015; 10(12):e0145849. PubMed ID: 26720709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of G protein-coupled receptor 39 impairs insulin secretion in vivo.
    Tremblay F; Richard AM; Will S; Syed J; Stedman N; Perreault M; Gimeno RE
    Endocrinology; 2009 Jun; 150(6):2586-95. PubMed ID: 19213841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G protein-coupled receptor 39 deficiency is associated with pancreatic islet dysfunction.
    Holst B; Egerod KL; Jin C; Petersen PS; Østergaard MV; Hald J; Sprinkel AM; Størling J; Mandrup-Poulsen T; Holst JJ; Thams P; Orskov C; Wierup N; Sundler F; Madsen OD; Schwartz TW
    Endocrinology; 2009 Jun; 150(6):2577-85. PubMed ID: 19213833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents.
    Lin DC; Zhang J; Zhuang R; Li F; Nguyen K; Chen M; Tran T; Lopez E; Lu JY; Li XN; Tang L; Tonn GR; Swaminath G; Reagan JD; Chen JL; Tian H; Lin YJ; Houze JB; Luo J
    PLoS One; 2011; 6(11):e27270. PubMed ID: 22087278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.
    Chu ZL; Jones RM; He H; Carroll C; Gutierrez V; Lucman A; Moloney M; Gao H; Mondala H; Bagnol D; Unett D; Liang Y; Demarest K; Semple G; Behan DP; Leonard J
    Endocrinology; 2007 Jun; 148(6):2601-9. PubMed ID: 17289847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPR39 receptors and actions of trace metals on pancreatic beta cell function and glucose homoeostasis.
    Moran BM; Abdel-Wahab YH; Vasu S; Flatt PR; McKillop AM
    Acta Diabetol; 2016 Apr; 53(2):279-93. PubMed ID: 26112416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats.
    Meidute Abaraviciene S; Muhammed SJ; Amisten S; Lundquist I; Salehi A
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):150-9. PubMed ID: 23911664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and characterization of novel small molecule agonists of G protein-coupled receptor 119.
    Zhang SY; Li J; Xie X
    Acta Pharmacol Sin; 2014 Apr; 35(4):540-8. PubMed ID: 24681896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homology modeling of FFA2 identifies novel agonists that potentiate insulin secretion.
    Villa SR; Mishra RK; Zapater JL; Priyadarshini M; Gilchrist A; Mancebo H; Schiltz GE; Layden BT
    J Investig Med; 2017 Dec; 65(8):1116-1124. PubMed ID: 28784695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-Based Discovery of Synthetic Agonists for the Zn
    Frimurer TM; Mende F; Graae AS; Engelstoft MS; Egerod KL; Nygaard R; Gerlach LO; Hansen JB; Schwartz TW; Holst B
    J Med Chem; 2017 Feb; 60(3):886-898. PubMed ID: 28045522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.
    Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M
    Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice.
    Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
    Biochem Biophys Res Commun; 2010 Nov; 402(2):280-5. PubMed ID: 20937249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion.
    Tanaka H; Yoshida S; Oshima H; Minoura H; Negoro K; Yamazaki T; Sakuda S; Iwasaki F; Matsui T; Shibasaki M
    J Pharmacol Exp Ther; 2013 Sep; 346(3):443-52. PubMed ID: 23853170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The acute glucose lowering effect of specific GPR120 activation in mice is mainly driven by glucagon-like peptide 1.
    Sundström L; Myhre S; Sundqvist M; Ahnmark A; McCoull W; Raubo P; Groombridge SD; Polla M; Nyström AC; Kristensson L; Någård M; Winzell MS
    PLoS One; 2017; 12(12):e0189060. PubMed ID: 29206860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic Islet APJ Deletion Reduces Islet Density and Glucose Tolerance in Mice.
    Han S; Englander EW; Gomez GA; Rastellini C; Quertermous T; Kundu RK; Greeley GH
    Endocrinology; 2015 Jul; 156(7):2451-60. PubMed ID: 25965959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent.
    Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Cheewatrakoolpong B; Xue J; Szeto D; Forrest G; Miller C; Bunzel M; Plummer CW; Chobanian HR; Miller MW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Li X; Feng Y; Tatosian DA; Howard AD; Colletti SL; Trujillo ME
    PLoS One; 2017; 12(10):e0186033. PubMed ID: 29053717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the insulin-releasing and glucose-lowering effects of GPR120 activation in pancreatic β-cells.
    Moran BM; Abdel-Wahab YH; Flatt PR; McKillop AM
    Diabetes Obes Metab; 2014 Nov; 16(11):1128-39. PubMed ID: 24919766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice.
    Moran BM; Abdel-Wahab YH; Flatt PR; McKillop AM
    Biol Chem; 2014 Apr; 395(4):453-64. PubMed ID: 24323890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.